Loading clinical trials...
Loading clinical trials...
A Phase Ib, Open Label, Single Arm, Multi-center, Dose Escalation Trial of Intravenous BI 836826 in Combination With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Conditions
Interventions
BI 836826
Ibrutinib
Locations
3
United States
City of Hope
Duarte, California, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Oregon Health and Sciences University
Portland, Oregon, United States
Start Date
June 23, 2016
Primary Completion Date
June 3, 2019
Completion Date
July 9, 2019
Last Updated
September 29, 2020
NCT07162181
NCT02869529
NCT04210219
NCT03190330
NCT06205290
NCT03425591
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions